Novo Nordisk's Tresiba (insulin degludec) has received its first positive approval opinion worldwide, in Japan, following a regulatory filing in this market last December.
The long-acting, once-daily basal insulin analogue is indicated for both type 1 and 2 disease and will provide competition to Sanofi's Lantus (insulin glargine) in the country's basal insulin market (scripintelligence.com, 28 December 2011)